Modular Design of Redox-Responsive Stabilizers for Nanocrystals
Source abstract
Abstract
Many potent drugs are difficult to administer intravenously due to poor aqueous solubility. A common approach for addressing this issue is to process them into colloidal dispersions known as "nanocrystals" (NCs). However, NCs possess high-energy surfaces that must be stabilized with surfactants to prevent aggregation. An optimal surfactant should have high affinity for the nanocrystal's surface to stabilize it, but may also include a trigger mechanism that could offer the possibility of altering size distribution and uptake of the NC. This study presents a modular and systematic strategy for optimizing the affinity of polymeric stabilizers for drug nanocrystals both before and after oxidation (i.e., the selected trigger), thus allowing for the optimal responsiveness for a given application to be identified. A library of 10 redox-responsive polymer stabilizers was prepared by postpolymerization modification, using the thiol-yne reaction, of two parent block copolymers. The stabilizing potential of these polymers for paclitaxel NCs is presented as well as the influence of oxidation on size and dissolution following exposure to reactive oxygen species (ROS), which are strongly associated with chronic inflammation and cancer. Owing to the versatility of postpolymerization modification, this contribution provides general tools for preparing triggered-sheddable stabilizing coatings for nanoparticles.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Iron oxide chemistry and applications · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich (ETH Zürich), Wolfgang-Pauli-Straße 10, 8093 Zurich, Switzerland
References (41)
Show source-provided references
1. Budijono S. J. · Colloids Surf. Physicochem. Eng. Aspects · 2010 · 360 · 10510.1016/j.colsurfa.2010.02.016 ↗
2. Alexis F. · Mol. Pharmaceutics · 2008 · 5 · 50510.1021/mp800051m ↗
3. Gaucher G. · Biomacromolecules · 2009 · 10 · 40810.1021/bm801178f ↗
4. Cormode D. P. · Bioconjugate Chem. · 2011 · 22 · 35310.1021/bc1003179 ↗
5. Schweiger C. · Int. J. Pharm. · 2011 · 408 · 13010.1016/j.ijpharm.2010.12.046 ↗
6. Romberg B. · Pharm. Res. · 2008 · 25 · 5510.1007/s11095-007-9348-7 ↗
7. Sankaranarayanan J. · ACS Nano · 2010 · 4 · 593010.1021/nn100968e ↗
8. Knipe J. M. · Nano Today · 2013 · 8 · 2110.1016/j.nantod.2012.12.004 ↗
9. Motion J. P. M. · Angew. Chem., Int. Ed. · 2012 · 51 · 904710.1002/anie.201204198 ↗
10. Fang J. · Adv. Drug Delivery Rev. · 2009 · 61 · 29010.1016/j.addr.2009.02.005 ↗
11. Preston T. J. · Adv. Drug Delivery Rev. · 2001 · 49 · 4510.1016/S0169-409X(01)00127-2 ↗
12. de Gracia Lux C. · J. Am. Chem. Soc. · 2012 · 134 · 1575810.1021/ja303372u ↗
13. Broaders K. E. · J. Am. Chem. Soc. · 2010 · 133 · 75610.1021/ja110468v ↗
14. Khutoryanskiy V. V. · Pure Appl. Chem. · 2008 · 80 · 170310.1351/pac200880081703 ↗
15. Allen B. L. · ACS Nano · 2011 · 5 · 526310.1021/nn201477y ↗
16. Rehor A. · Langmuir · 2004 · 21 · 41110.1021/la0478043 ↗
17. Yu S. S. · Biomacromolecules · 2011 · 12 · 435710.1021/bm201328k ↗
18. Gao W. · Angew. Chem., Int. Ed. · 2010 · 49 · 656710.1002/anie.201001868 ↗
19. Gauthier M. A. · Angew. Chem., Int. Ed. · 2009 · 48 · 4810.1002/anie.200801951 ↗
20. Hoogenboom R. · Angew. Chem., Int. Ed. · 2010 · 49 · 341510.1002/anie.201000401 ↗
21. Napoli A. · Nat. Mater. · 2004 · 3 · 18310.1038/nmat1081 ↗
22. Kim M. S. · Macromol. Rapid Commun. · 2005 · 26 · 64310.1002/marc.200400650 ↗
23. Bertrand N. · J. Controlled Release · 2012 · 161 · 15210.1016/j.jconrel.2011.09.098 ↗
24. Aggarwal P. · Adv. Drug Delivery Rev. · 2009 · 61 · 42810.1016/j.addr.2009.03.009 ↗
25. Torchilin V. P. · Adv. Drug Delivery Rev. · 2006 · 58 · 153210.1016/j.addr.2006.09.009 ↗
26. Cerdeira A. M. · Int. J. Pharm. · 2010 · 396 · 21010.1016/j.ijpharm.2010.06.020 ↗
27. Van Eerdenbrugh B. · Mol. Pharmaceutics · 2010 · 7 · 185810.1021/mp100209b ↗
28. Pasche S. · Langmuir · 2003 · 19 · 921610.1021/la034111y ↗
29. Szela S. · Biomacromolecules · 2000 · 1 · 53410.1021/bm0055697 ↗
30. Dado G. P. · J. Am. Chem. Soc. · 1993 · 115 · 1260910.1021/ja00079a060 ↗
31. Carampin P. · Macromol. Chem. Phys. · 2012 · 213 · 205210.1002/macp.201200264 ↗
32. Mahmoud E. A. · Bioconjugate Chem. · 2011 · 22 · 141610.1021/bc200141h ↗
33. Alexandre J. · Int. J. Cancer · 2006 · 119 · 4110.1002/ijc.21685 ↗
34. Alexandre J. · Cancer Res. · 2007 · 67 · 351210.1158/0008-5472.CAN-06-3914 ↗
35. Duncan R. · Mol. Pharm. · 2011 · 8 · 210110.1021/mp200394t ↗
36. Basiruddin S. K. · J. Phys. Chem. C · 2010 · 114 · 1100910.1021/jp100844d ↗
37. Yu S. · J. Nanobiotechnol. · 2011 · 9 · 710.1186/1477-3155-9-7 ↗
38. Mailänder V. · Biomacromolecules · 2009 · 10 · 237910.1021/bm900266r ↗
39. Dubertret B. · Science · 2002 · 298 · 175910.1126/science.1077194 ↗
40. Fuhrmann K. · ACS Nano · 2012 · 6 · 166710.1021/nn2046554 ↗
41. Letchford K. · Eur. J. Pharm. Biopharm. · 2009 · 71 · 19610.1016/j.ejpb.2008.08.003 ↗